U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07207681) titled 'Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors' on Aug. 01.
Brief Summary: This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.
Study Start Date: Oct. 15
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: KXV01 TCR Lentinvivo Injection
KXV01 TCR Lentinvivo Injection is one kind of third-generation non-replicative self-inactivating lentivirus vector which carries an effective patient's personalized tumor-reacti...